Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -384.39 Million SEK | 8.9% |
| 2022 | -421.94 Million SEK | 19.55% |
| 2021 | -524.45 Million SEK | -38.12% |
| 2020 | -379.72 Million SEK | -1255.22% |
| 2019 | -28.01 Million SEK | 78.85% |
| 2018 | -132.48 Million SEK | -56.77% |
| 2017 | -84.5 Million SEK | -50.86% |
| 2016 | -56.02 Million SEK | -10.04% |
| 2015 | -50.91 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -203.82 Million SEK | -792.84% |
| 2024 Q2 | -34.19 Million SEK | 83.22% |
| 2023 Q1 | -184.1 Million SEK | -1389.25% |
| 2023 FY | -384.39 Million SEK | 8.9% |
| 2023 Q4 | 29.41 Million SEK | 118.44% |
| 2023 Q3 | -159.57 Million SEK | -112.28% |
| 2023 Q2 | -75.17 Million SEK | 59.17% |
| 2022 Q4 | -12.36 Million SEK | 65.88% |
| 2022 Q2 | -209.84 Million SEK | -0.71% |
| 2022 Q1 | -208.36 Million SEK | 6.2% |
| 2022 FY | -421.94 Million SEK | 19.55% |
| 2022 Q3 | -36.22 Million SEK | 82.74% |
| 2021 Q4 | -222.13 Million SEK | -2927.56% |
| 2021 Q1 | -150.78 Million SEK | -10.92% |
| 2021 Q2 | -159.39 Million SEK | -5.71% |
| 2021 FY | -524.45 Million SEK | -38.12% |
| 2021 Q3 | 7.85 Million SEK | 104.93% |
| 2020 Q1 | -72.32 Million SEK | -300.85% |
| 2020 Q2 | -66.56 Million SEK | 7.97% |
| 2020 FY | -379.72 Million SEK | -1255.22% |
| 2020 Q4 | -135.94 Million SEK | -29.6% |
| 2020 Q3 | -104.89 Million SEK | -57.58% |
| 2019 Q4 | -18.04 Million SEK | 65.72% |
| 2019 Q2 | 85.38 Million SEK | 299.85% |
| 2019 Q3 | -52.63 Million SEK | -161.65% |
| 2019 FY | -28.01 Million SEK | 78.85% |
| 2019 Q1 | -42.72 Million SEK | 4.52% |
| 2018 Q4 | -44.74 Million SEK | -43.08% |
| 2018 FY | -132.48 Million SEK | -56.77% |
| 2018 Q3 | -31.27 Million SEK | -71.76% |
| 2018 Q2 | -18.2 Million SEK | 52.41% |
| 2018 Q1 | -38.25 Million SEK | 5.63% |
| 2017 Q3 | -17.47 Million SEK | -12.83% |
| 2017 Q1 | -11 Million SEK | 0.0% |
| 2017 Q2 | -15.48 Million SEK | -40.68% |
| 2017 Q4 | -40.53 Million SEK | -132.0% |
| 2017 FY | -84.5 Million SEK | -50.86% |
| 2016 FY | -56.02 Million SEK | -10.04% |
| 2015 FY | -50.91 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -54.387% |
| Ziccum AB (publ) | -21.56 Million SEK | -1682.917% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -2243.741% |
| BioArctic AB (publ) | 252.64 Million SEK | 252.152% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -45390.769% |
| Mendus AB (publ) | -100.65 Million SEK | -281.915% |
| Genovis AB (publ.) | 54.22 Million SEK | 808.906% |
| Intervacc AB (publ) | -93.57 Million SEK | -310.773% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -2378.062% |
| Active Biotech AB (publ) | -46.48 Million SEK | -726.945% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 2234.472% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -593.645% |
| Aptahem AB (publ) | -10.1 Million SEK | -3704.118% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | -19.561% |
| Kancera AB (publ) | -65.04 Million SEK | -490.998% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -185.549% |
| Fluicell AB (publ) | -26.87 Million SEK | -1330.102% |
| Saniona AB (publ) | -81.06 Million SEK | -374.184% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -3007.243% |
| Biovica International AB (publ) | -126.07 Million SEK | -204.9% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -804.357% |
| AcouSort AB (publ) | -17.48 Million SEK | -2098.187% |
| Xintela AB (publ) | -57.23 Million SEK | -571.577% |
| Abliva AB (publ) | -96.54 Million SEK | -298.141% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | -18.349% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -10867.104% |
| OncoZenge AB (publ) | -15.9 Million SEK | -2317.287% |
| Amniotics AB (publ) | -29.07 Million SEK | -1222.179% |
| 2cureX AB (publ) | -36.36 Million SEK | -957.11% |
| CombiGene AB (publ) | -36.3 Million SEK | -958.794% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -2525.663% |
| Camurus AB (publ) | 532.35 Million SEK | 172.207% |
| Corline Biomedical AB | -1.78 Million SEK | -21398.714% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -112.65% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -822.191% |
| I-Tech AB | 24.43 Million SEK | 1673.141% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 51.249% |
| Cyxone AB (publ) | -21.66 Million SEK | -1674.604% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -262.758% |
| Biosergen AB | -27.26 Million SEK | -1309.855% |
| Cantargia AB (publ) | -290.01 Million SEK | -32.543% |
| NextCell Pharma AB | -43.17 Million SEK | -790.382% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -112.65% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -2148.425% |
| Nanologica AB (publ) | -69.96 Million SEK | -449.429% |
| SynAct Pharma AB | -224.49 Million SEK | -71.227% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -770.149% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1504.712% |
| LIDDS AB (publ) | -40.67 Million SEK | -845.068% |
| Lipum AB (publ) | -37.25 Million SEK | -931.827% |
| BioInvent International AB (publ) | -369.94 Million SEK | -3.907% |
| Alzinova AB (publ) | -16.52 Million SEK | -2226.577% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -51.668% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -5912.545% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -234.046% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1808.719% |
| Simris Alg AB (publ) | -36.63 Million SEK | -949.262% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -162.267% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | -23.829% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -246.572% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -3223.509% |